You do not have permission to edit this page, for the following reasons:

This IP address has been blocked from editing Wikipedia.
This does not affect your ability to read Wikipedia pages.
Most people who see this message have done nothing wrong. Some kinds of blocks restrict editing from specific service providers or telecom companies in response to recent abuse or vandalism, and can sometimes affect other users who are unrelated to that abuse. Review the information below for assistance if you do not believe that you have done anything wrong.

The IP address or range 44.197.0.0/16 has been blocked (disabled) by ‪Blablubbs‬ for the following reason(s):

The IP address that you are currently using has been blocked because it is believed to be a web host provider or colocation provider. To prevent abuse, web hosts and colocation providers may be blocked from editing Wikipedia.
You will not be able to edit Wikipedia using a web host or colocation provider because it hides your IP address, much like a proxy or VPN.
We recommend that you attempt to use another connection to edit. For example, if you use a proxy or VPN to connect to the internet, turn it off when editing Wikipedia. If you edit using a mobile connection, try using a Wi-Fi connection, and vice versa. If you are using a corporate internet connection, switch to a different Wi-Fi network. If you have a Wikipedia account, please log in.
If you do not have any other way to edit Wikipedia, you will need to request an IP block exemption.

How to appeal if you are confident that your connection does not use a colocation provider's IP address:
If you are confident that you are not using a web host, you may appeal this block by adding the following text on your talk page: ((unblock|reason=Caught by a colocation web host block but this host or IP is not a web host. My IP address is _______. Place any further information here. ~~~~)). You must fill in the blank with your IP address for this block to be investigated. Your IP address can be determined here. Alternatively, if you wish to keep your IP address private you can use the unblock ticket request system. There are several reasons you might be editing using the IP address of a web host or colocation provider (such as if you are using VPN software or a business network); please use this method of appeal only if you think your IP address is in fact not a web host or colocation provider.

Administrators: The IP block exemption user right should only be applied to allow users to edit using web host in exceptional circumstances, and requests should usually be directed to the functionaries team via email. If you intend to give the IPBE user right, a CheckUser needs to take a look at the account. This can be requested most easily at SPI Quick Checkuser Requests. Unblocking an IP or IP range with this template is highly discouraged without at least contacting the blocking administrator.

This block will expire on 10:52, 20 August 2024.

Even when blocked, you will usually still be able to edit your user talk page, as well as email administrators and other editors.

For information on how to proceed, please read the FAQ for blocked users and the guideline on block appeals. The guide to appealing blocks may also be helpful.

Other useful links: Blocking policy · Help:I have been blocked
Your IP address is in a range that has been blocked on all Wikimedia Foundation wikis. The block was made by ‪AntiCompositeNumber‬. The reason given is Open proxy/Webhost: Visit the FAQ if you are affected .
- Start of block: 13:55, 18 August 2022
- Expiry of block: 13:55, 18 November 2024
Your current IP address is 44.197.119.13. The blocked range is 44.197.0.0/16. Please include all above details in any queries you make. If you believe you were blocked by mistake, you can find additional information and instructions in the No open proxies global policy. Otherwise, to discuss the block please post a request for review on Meta-Wiki. You could also send an email to the stewards VRT queue at stewards@wikimedia.org including all above details.

You can view and copy the source of this page:

((Use mdy dates|date=September 2017))
((more citations needed|date=April 2012))

The '''Drug Effectiveness Review Project''' (DERP) is a self-governed collaboration of state [[Medicaid]] and public pharmacy programs that commission high-quality evidence-based research products to assist policymakers and other decision-makers grappling with difficult drug coverage decisions. Housed at the Center for Evidence-based Policy at [[Oregon Health & Science University]] in Portland, [[Oregon]], DERP produces concise, comparative, evidence-based research products that evaluate the efficacy, effectiveness, and safety of [[drugs]] in many widely used drug classes.

Nationally recognized for its clinical objectivity and high-quality research, DERP focuses on specialty and other high-impact drugs – particularly those that have potential to change clinical practice. The program's goal is to ultimately help improve appropriate patient access, safety, and quality of care while helping government programs contain exploding costs for new pharmaceutical therapies. DERP uses a collaborative governing model to develop work plans that provide independent and objective research on drug effectiveness and safety to bring evidence to health policy decisions.

DERP reports include up-to-date clinical evidence on efficacy, adverse events, and safety information for the drugs reviewed. These reports and research products are not usage guidelines, nor should they be read as an endorsement of or recommendation for any particular drug, use or approach. Rather, DERP reports are used by policy makers to develop criteria for drug coverage, such as prior authorizations, clinical edits, drug utilization management policies, and provider or patient education materials. DERP research products include a comprehensive search of the global evidence, an objective appraisal of the quality of the studies found, and a thorough synthesis of high-quality evidence. Policymakers are able to use these reports and research products to make informed policy decisions that improve patient outcomes and contain costs.

==Sources==
*((Cite journal | last1 = Neumann | first1 = P. J. | title = Emerging Lessons from the Drug Effectiveness Review Project | doi = 10.1377/hlthaff.25.w262 | journal = Health Affairs | volume = 25 | issue = 4 | pages = W262–W271 | year = 2006 | pmid =  16757486| doi-access =  ))
*((Cite journal | last1 = Donohue | first1 = J. M. | last2 = Fischer | first2 = M. A. | last3 = Huskamp | first3 = H. A. | last4 = Weissman | first4 = J. S. | title = Potential Savings from an Evidence-Based Consumer-Oriented Public Education Campaign on Prescription Drugs | doi = 10.1111/j.1475-6773.2008.00858.x | journal = Health Services Research | volume = 43 | issue = 5p1 | pages = 1557–1575 | year = 2008 | pmid =  18479406| pmc = 2653882))

==External links==
*[https://centerforevidencebasedpolicy.org/our-approach/derp/ The Drug Effectiveness Review Project]

[[Category:Pharmacological societies]]
[[Category:Systematic review]]


((drug-stub))

Pages transcluded onto the current version of this page (help):

Drug Effectiveness Review Project (edit)
Template:Ambox (view source) (template editor protected)
Template:Asbox (view source) (template editor protected)
Template:Asbox/styles.css (view source) (template editor protected)
Template:Cite journal (view source) (protected)
Template:DMCA (view source) (template editor protected)
Template:Dated maintenance category (view source) (template editor protected)
Template:Dated maintenance category (articles) (view source) (template editor protected)
Template:Drug-stub (edit)
Template:FULLROOTPAGENAME (view source) (template editor protected)
Template:Find sources mainspace (view source) (template editor protected)
Template:Hlist/styles.css (view source) (protected)
Template:Main other (view source) (protected)
Template:More citations needed (view source) (template editor protected)
Template:Ns has subpages (view source) (protected)
Template:Pharma-stub (view source) (semi-protected)
Template:Use mdy dates (view source) (template editor protected)
Module:Arguments (view source) (protected)
Module:Asbox (view source) (template editor protected)
Module:Buffer (view source) (template editor protected)
Module:Category handler (view source) (protected)
Module:Category handler/blacklist (view source) (protected)
Module:Category handler/config (view source) (protected)
Module:Category handler/data (view source) (protected)
Module:Category handler/shared (view source) (protected)
Module:Check for unknown parameters (view source) (protected)
Module:Citation/CS1 (view source) (protected)
Module:Citation/CS1/COinS (view source) (protected)
Module:Citation/CS1/Configuration (view source) (protected)
Module:Citation/CS1/Date validation (view source) (protected)
Module:Citation/CS1/Identifiers (view source) (protected)
Module:Citation/CS1/Utilities (view source) (protected)
Module:Citation/CS1/Whitelist (view source) (protected)
Module:Citation/CS1/styles.css (view source) (protected)
Module:Find sources (view source) (template editor protected)
Module:Find sources/config (view source) (template editor protected)
Module:Find sources/links (view source) (template editor protected)
Module:Find sources/templates/Find sources mainspace (view source) (template editor protected)
Module:Message box (view source) (protected)
Module:Message box/ambox.css (view source) (protected)
Module:Message box/configuration (view source) (protected)
Module:Namespace detect/config (view source) (protected)
Module:Namespace detect/data (view source) (protected)
Module:Navbar (view source) (protected)
Module:Navbar/configuration (view source) (protected)
Module:Navbar/styles.css (view source) (protected)
Module:Ns has subpages (view source) (template editor protected)
Module:Unsubst (view source) (protected)
Module:Yesno (view source) (protected)

Return to Drug Effectiveness Review Project.

Retrieved from "https://en.wikipedia.org/wiki/Drug_Effectiveness_Review_Project"